Soligenix covid-19 vaccine, civax™, boosts neutralizing activity against sars-cov-2, including delta and omicron

Civax™ booster vaccine administered seven months after primary vaccination with covid-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates neutralizing antibodies against delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks omicron neutralizing antibody levels were undetectable prior to booster vaccination, and attained presumed protective levels within one week of vaccination princeton, n.j., march 17, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the results of a booster vaccination study using civax™ (heat stable covid-19 subunit vaccine program) in non-human primates (nhps) demonstrating rapid enhancement of neutralizing antibody responses to sars-cov-2, including against delta and omicron variants.
SNGX Ratings Summary
SNGX Quant Ranking